Amber McMahan
Acute Care · Dalton, GANPI 1952852949
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 438 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,010, 2.2 times the $898 reported in 2021. Among acute care clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 438 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$986
- OPKO Pharmaceuticals, LLC$899
- Otsuka America Pharmaceutical, Inc.$764
- Bayer$685
- Amgen$567
- Travere Therapeutics, Inc.$558
- plus $3K from 23 others
What the payments were for
- Food & beverage$7,45999%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 51 | $986 |
| OPKO Pharmaceuticals, LLC | 107 | $899 |
| Otsuka America Pharmaceutical, Inc. | 38 | $764 |
| Bayer | 39 | $685 |
| Amgen(2 entities) | 29 | $567 |
| Travere Therapeutics, Inc. | 27 | $558 |
| Fresenius USA Marketing, Inc. | 27 | $502 |
| Vifor Pharma, Inc. | 20 | $389 |
| Mallinckrodt Hospital Products Inc. | 10 | $264 |
| Calliditas Therapeutics US Inc. | 11 | $254 |
| ANI Pharmaceuticals, Inc. | 10 | $228 |
| Novartis | 9 | $219 |
| Ardelyx, Inc. | 9 | $182 |
| Akebia Therapeutics Inc | 7 | $149 |
| Novo Nordisk | 6 | $138 |
| Boehringer Ingelheim | 8 | $134 |
| Aurinia Pharma U.S., Inc. | 4 | $111 |
| Daiichi Sankyo Inc. | 3 | $86 |
| GSK | 6 | $85 |
| Lilly USA, LLC | 4 | $79 |
| Scpharmaceuticals Inc. | 5 | $75 |
| Shield Therapeutics Inc | 1 | $25 |
| Sanofi | 1 | $22 |
| Averitas Pharma Inc. | 1 | $21 |
| Cormedix Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Vantive US Healthcare LLC | 1 | $16 |
| AbbVie | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$7,502 in reported general payments places this provider in the 95th percentile of 679 acute care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 30 | $37,305 |
| JardianceEmpagliflozin | 25 | $28,719 |
| FarxigaDapagliflozin Propanediol | 23 | $23,514 |
| Torsemide | 22 | $847 |
| Spironolactone | 47 | $443 |
| Amlodipine Besylate | 56 | $424 |
| Famotidine | 26 | $419 |
| Furosemide | 77 | $383 |
| Doxazosin Mesylate | 20 | $344 |
| Nifedipine ErNifedipine | 16 | $338 |
| Hydralazine Hcl | 19 | $288 |
| Metoprolol Succinate | 14 | $278 |
| Tamsulosin Hcl | 18 | $250 |
| Carvedilol | 22 | $243 |
| Allopurinol | 31 | $236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $685 | $37,30530 claims |
| Boehringer IngelheimJardiance | $134 | $28,71925 claims |
| AstraZenecaFarxiga | $986 | $23,51423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 acute care providers in Georgia.
Other acute care in Dalton
- Lindsey KiddDalton$4K
- Megan FarmerDalton$3K
- Darryl TurnerRinggold$21K
- Bryce CowgillCumming$16K
- Stacy CreelSavannah$15K
- Susan BeitzellAthens$13K
- Crystal KuhnCumming$12K
- Mark ClarkGainesville$10K
- Sarah WymanAtlanta$10K
- Jeffrey DillerAustell$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.